Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

ISA 2020 | RNAi therapeutics for ATTR amyloidosis

Mathew Maurer • 23 Sep 2020
ISA 2020
Amyloidosis Rare Diseases

Mathew Maurer, MD, Columbia University, New York, NY, discusses the use of RNAi therapeutics for ATTR amyloidosis. This interview was recorded via an online conference call with The Video Journal of Hematological Oncology (VJHemOnc).

More from Mathew Maurer

2:09
Heart transplantation in ATTR amyloidosis
Mathew Maurer • 16 Sep 2020
1:53
DISCOVERY: cardiac amyloidosis screening study
Mathew Maurer • 3 Sep 2020

Related Videos

3:18
Immune-mediated bone marrow failure diseases & their pathophysiology: aplastic anemia, LR-MDS & PNH
Carlo Dufour • 15 Apr 2024
1:11
Personalized risk assessment for transplantation in primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
1:18
Autologous gene editing using the CRISPR system to treat primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
0:58
Hematological manifestations associated with primary immunodeficiency disorders
Thomas Fox • 15 Apr 2024
The content of VJHemOnc is intended for healthcare professionals